CSIMarket
 



Igm Biosciences Inc   (IGMS)
Other Ticker:  
 
 



 

What are Igm Biosciences Inc's Business Segments?



Segments:
Igm Biosciences Inc operates in the biotechnology and pharmaceutical industry. The company primarily focuses on the development of immunoglobulin M (IgM) antibodies for the treatment of various diseases. The company is engaged in the research and development, manufacturing, and commercialization of IgM drugs.

Products:
1. IGM-2323: It is a bispecific antibody that targets CD20 and CD3 for the treatment of B cell malignancies. The product is currently in phase 1 clinical trials.

2. IGM-8444: It is a bispecific antibody that targets PD-L1 and LAG-3 for the treatment of various cancers. The product is in preclinical development.

3. IGM-7354: It is a bispecific antibody that targets CD47 and CD19 for the treatment of B cell malignancies. The product is in preclinical development.

4. IGM-7650: It is a bispecific antibody that targets CD20 and CD47 for the treatment of B cell malignancies. The product is in preclinical development.

Services:
Igm Biosciences Inc is primarily focused on the development of novel IgM antibodies for the treatment of cancers and various diseases. The company offers the following services:

1. Research and Development: The company offers research and development services to develop novel IgM antibodies for the treatment of various diseases.

2. Manufacturing: The company provides manufacturing services for the production of IgM antibodies for clinical and commercial use.

3. Clinical Trials: The company offers clinical trial services for the testing of its IgM antibodies in humans.

4. Regulatory Affairs: The company offers regulatory affairs services for the approval of its IgM antibody products by regulatory authorities.
   

Igm Biosciences Inc Tax Rate Companies within the Major Pharmaceutical Preparations Industry


Business Segments Q3
Revenues
(in millions $)
Q3
Income
(in millions $)
(Sep 30 2023)
%
(Profit Margin)
Total 0.51 -61.99 -

Growth rates by Segment Q3
Y/Y Revenue
%
(Sep 30 2023)
Q/Q Revenue
%
Q3
Y/Y Income
%
(Sep 30 2023)
Q/Q Income
%
Total - - - -

To get more information on Igm Biosciences Inc's Total segment. Select each division with the arrow.


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com